Improving survival outcomes of childhood acute lymphoblastic leukemia: A 25‐year experience from a single center in Saudi Arabia

The development of cancer programs in developing countries to meet the standards observed in high‐income developed countries is not well documented.

[1]  W. Jastaniah,et al.  Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia , 2018, Experimental Hematology & Oncology.

[2]  W. Jastaniah,et al.  High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia , 2018, Leukemia research reports.

[3]  B. Rachet,et al.  Childhood cancer incidence and survival in Japan and England: A population‐based study (1993‐2010) , 2017, Cancer science.

[4]  R. Ribeiro,et al.  A framework to develop adapted treatment regimens to manage pediatric cancer in low‐ and middle‐income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP) , 2017, Pediatric blood & cancer.

[5]  M. Loh,et al.  Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Abrar,et al.  Comparison of clinical trial versus non-clinical trial treatment outcomes of childhood acute lymphoblastic leukemia using comparable regimens , 2016, Hematology.

[7]  M. Abrar,et al.  Identifying causes of variability in outcomes in children with acute lymphoblastic leukemia treated in a resource‐rich developing country , 2015, Pediatric blood & cancer.

[8]  M. Abrar,et al.  Does the early intensification of intrathecal therapy improve outcomes in pediatric acute lymphoblastic leukemia patients with CNS2/TLP+ status at diagnosis? , 2015, Hematology.

[9]  M. Loh,et al.  T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434 , 2014 .

[10]  S. Altekruse,et al.  Declining childhood and adolescent cancer mortality , 2014, Cancer.

[11]  M. Abrar,et al.  Improved outcome in pediatric AML due to augmented supportive care , 2012, Pediatric blood & cancer.

[12]  Xiaomin Lu,et al.  Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[14]  C. Fryer,et al.  Acute Lymphoblastic Leukemia in Children: A Fifteen Year Experience at the Princess Nourah Oncology Center, Jeddah, Saudi Arabia. , 2006 .